On February 23, 2023 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, reported results from their clinical trial entitled, "An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors (KOURAGE)" have been published in the Volume 8, Issue 12, December, 2022, e12450 issue of Heliyon (Press release, Bexion, FEB 23, 2023, View Source [SID1234627638]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights of this study included:

A review of the Phase 1 dose escalation study of BXQ-350 in pediatric solid tumors including CNS.
BXQ-350 is a well-tolerated intravenous drug and achieved the Maximum Planned Dose.
"Results from this pediatric phase 1 study reinforces the excellent safety profile we observed in our adult phase 1 study of BXQ-350 in advanced solid tumors and recurrent high-grade glioma," stated Scott Shively, President and CEO. "Our safety and maximum planned dose objectives were met in this study, enabling Bexion to open a pediatric phase 1 study in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG), advancing our commitment to pediatric cancer research."